Liposarcoma

• EMA approval · 2026-02-24
  EMA Authorised: Eribulin Baxter (Eribulin mesylate) — Baxter Holding B.V.

  EMA authorised Eribulin Baxter (eribulin mesylate) for treatment of breast neoplasms and liposarcoma; the marketing authorisation holder is …

• FDA approval · 2025-08-05
  FDA Approved: ERIBULIN MESYLATE — Original Application (Kindos Pharmaceuticals Co., Ltd.)

  FDA approves an original application for Eribulin Mesylate from Kindos Pharmaceuticals Co., Ltd., enabling its generic product to enter the …

• FDA approval · 2025-07-03
  FDA Approved: ERIBULIN MESYLATE — Original Application (Dr. Reddys Laboratories Inc)

  FDA approves Dr. Reddy's Laboratories' original ANDA for eribulin mesylate, a generic version of the anticancer agent.

• FDA approval · 2025-06-09
  FDA Approved: ERIBULIN MESYLATE — Original Application (Sandoz Inc)

  The FDA approved Sandoz's original ANDA for ERIBULIN MESYLATE, authorizing the generic product's marketing in the United States.

• FDA approval · 2025-03-04
  FDA Approved: ERIBULIN MESYLATE — Original Application (Sun Pharmaceutical Industries Limited)

  FDA approved Sun Pharmaceutical Industries Limited's original ANDA for eribulin mesylate, confirming a generic version of the cancer drug. T…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2024-10-16
  EMA Authorised: Mevlyq (Eribulin mesylate) — YES Pharmaceutical Development Services GmbH

  The EMA authorised Mevlyq (eribulin mesylate) for breast cancer and liposarcoma, with marketing authorisation holder YES Pharmaceutical Deve…

• EMA approval · 2024-10-11
  EMA Authorised: Halaven (Eribulin) — Eisai GmbH

  The EMA authorised Halaven (eribulin) for breast neoplasms and liposarcoma under Eisai GmbH, with a decision date of 26 July 2024.

• FDA approval · 2024-07-18
  FDA Approved: ERIBULIN MESYLATE — Original Application (BluePoint Laboratories)

  FDA approved BluePoint Laboratories' original ANDA for eribulin mesylate, authorizing the generic manufacturing of this cancer drug.

• FDA approval · 2024-04-05
  FDA Approved: ERIBULIN MESYLATE — Original Application (Gland Pharma Limited)

  FDA approved an original (generic) application for Eribulin Mesylate from Gland Pharma Limited, authorizing the generic version of the produ…

• FDA approval · 2018-06-29
  FDA Approved: YONDELIS — Supplemental Application (Janssen Products, LP)

  FDA approved a supplemental application for YONDELIS (trabectedin) from Janssen Products, LP.

• FDA approval · 2015-11-18
  FDA Approved: HALAVEN — Supplemental Application (BSP Pharmaceuticals SpA)

  FDA approved a supplemental application for HALAVEN (eribulin mesylate) from BSP Pharmaceuticals SpA.

• FDA approval · 2014-08-01
  FDA Approved: HALAVEN — Supplemental Application (BSP Pharmaceuticals SpA)

  The FDA approved a supplemental application for HALAVEN (eribulin mesylate) submitted by BSP Pharmaceuticals SpA.

• FDA approval · 2012-02-17
  FDA Approved: HALAVEN — Supplemental Application (BSP Pharmaceuticals SpA)

  FDA approved a supplemental application for HALAVEN (eribulin mesylate) submitted by BSP Pharmaceuticals SpA.